85102-99-4

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-1H-Imidazole-5-Carboxaldehyde is used as a synthetic intermediate for the development of novel drugs, particularly in the synthesis of Fadolmidine (F101040). Fadolmidine is a new α2-adrenoceptor (α2-AR) agonist that demonstrates antinociceptive properties, making it a potential candidate for the treatment of pain management.
In the synthesis of Fadolmidine, 1-Benzyl-1H-Imidazole-5-Carboxaldehyde plays a crucial role in the formation of the imidazole core structure, which is essential for the biological activity of the final product. The benzyl group provides steric and electronic effects that can influence the binding affinity and selectivity of the compound towards its target receptor, while the carboxaldehyde group can be further modified to introduce additional functional groups or moieties that enhance the drug's pharmacological properties.
Furthermore, 1-Benzyl-1H-Imidazole-5-Carboxaldehyde can be utilized in the development of other α2-adrenoceptor agonists or antagonists with potential applications in various therapeutic areas, such as cardiovascular diseases, central nervous system disorders, and metabolic conditions. Its versatility in organic synthesis allows for the exploration of structural modifications and the design of new chemical entities with improved potency, selectivity, and pharmacokinetic profiles.

InChI:InChI=1/C11H10N2O/c14-8-11-6-12-9-13(11)7-10-4-2-1-3-5-10/h1-6,8-9H,7H2

Upstream product

• 100-44-7 benzyl chloride 
• 3034-50-2 4⁽⁵⁾formylimidazole 
• 52726-21-3 5-methyl-1-(phenylmethyl)imidazole 
• 160999-35-9 1-Benzyl-5-(2-phenylethenyl)-1H-imidazole 
• 3034-50-2 5-imidazolecarboxaldehyde 
• 100-39-0 benzyl bromide 
• 626242-04-4 (1-benzyl-1H-5-imidazolyl)methyl acetate 
• 76075-21-3 ethyl 1-benzyl-1H-imidazole-5-carboxylic acid 
• 17674-16-7 benzyl triflate 
• 33016-47-6 (1-tritylimidazol-4-yl)carboxaldehyde 
• 100-46-9 benzylamine 
• 60293-41-6 N-((E)-3-phenylallylidene)benzylamine 
• 98412-23-8 1-benzyl-2-mercapto-5-hydroxymethyl-imidazole 

Downstream Products

• 86803-31-8 1-benzyl-5-vinyl-1H-imidazole 
• 80304-50-3 1-benzyl-5-hydroxymethylimidazole 
• 147223-87-8 1-benzyl-5-[4-(4-fluorophenyl)-1-hydroxybutyl]-1H-imidazole 
• 857352-35-3 (E/Z)-1-benzylimidazole-5-carbaldehyde oxime 
• 880106-38-7 4-[N-(1-benzyl-1H-imidazol-5-yl)methylamino]-2-phenylbenzoylmethionine methyl ester 
• 501096-88-4 1-benzylimidazole-5-methyl(N-benzhydrylamino)phosphonic acid 
• 147223-88-9 1-benzyl-5-[4-(4-fluorophenyl)-1-oxobutyl]-1H-imidazole 
• 147223-89-0 1-benzyl-5-[4-(4-fluorophenyl)-1-hydroxy-1-(4-tert-butylaminocarbonylphenyl)butyl]-1H-imidazole 

Relevant academic research and scientific papers

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as defined in the specification.

Structurally simple inhibitors of lanosterol 14α-demethylase are efficacious in a rodent model of acute Chagas disease

We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14α-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T. cruzi amastigotes in vitro with values of EC 50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.

Regiochemistry of N-substitution of some 4(5)-substituted imidazoles under solvent-free conditions

(Chemical Equation Presented) Imidazole-4(5)-carboxaldehyde and 4(5)-cyanoimidazole were N-benzylated and N-methylated using benzyl chloride and methyl iodide on zinc oxide (ZnO), alumina, and KF/alumina under basic conditions without solvent. Triethylamine (Et3N) or potassium carbonate was added as base in the reactions on ZnO and alumina. Imidazole-4(5)-carboxaldehyde was also benzylated on silica and carbon nanotubes. The effect of bases and solids on the product distribution of 1,4- and 1,5-substituted compounds was investigated. In some cases, the product ratios were different for imidazole-4(5)-carboxaldehyde and 4(5)-cyanoimidazole. In the reactions on KF/alumina the 1,4-product was favored for both compounds. The combination of Et3N and ZnO favored the 1,5-product, however for the nitrile effect was not so pronounced. When N-benzylation and methylation of the aldehyde were performed in the presence of catalytic amount of zinc chloride with Et3N as base, the product distributions were the same as in the reactions on ZnO. Nitrile gave different product ratios on ZnO and in the presence of ZnCl2. In addition, a mixture of N-benzylimidazole and 1,3-dibenzylimidazolium was produced when imidazole was benzylated on KF/alumina. Only the latter product was afforded when two equivalents of benzyl chloride were used.

Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3H- cycloheptimidazol-4-ones and 2-alkyl-3H-cycloheptimidazol-4-ones

Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3H- cycloheptimidazol-4-one (1) and 2-alkyl-3H-cycloheptimidazol-4-one (2) was investigated. 3-[2′-(1-tert-Butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2- propyl-5,6,7,8-tetrahydro-1H-cycloheptimidazol-4-one (6) was preferentially obtained under the conditions by using NaH in DMF or THF. On the other hand, 3-[2′-(1-tert-butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2-propyl-5,6,7, 8-tetrahydro-3H-cycloheptimidazol-4-one (5), the synthetic intermediate compound of Pratosartan, was obtained selectively in the presence of n-Bu4NBr in toluene by using aqueous sodium hydroxide as a base. In this reaction, it was found that the concentration of the alkaline solution influences its regioselectivity. This selectivity was observed even for aldehyde and ester derivatives.

Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase

A series of imidazole-containing peptidomimetic PFTase inhibitors and their co-crystal structures bound to PFTase and FPP are reported. The structures reveal that the peptidomimetics adopt a similar conformation to that of the extended CVIM tetrapeptide,

Novel N-(4-piperidinyl)benzamide antimalarials with mammalian protein farnesyltransferase inhibitory activity

Protein farnesyltransferase of Plasmodium falciparum is a potential target in the treatment of malaria for which increased drug resistance is observed. The design, synthesis and evaluation of a series of N-(4-piperidinyl)benzamides is reported. The most potent compounds showed in vitro activity against the parasite at submicromolar concentrations.

Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins

The invention concerns compounds of general formula (1), wherein, in particular; W represents H, SO2R5. CO(CH2)nR5, (CH2)nR6, CS(CH2)nR5; X represents S or NH; Y represents (CH2)p, CO, (CH2)pCO, CH═CH—CO; Z represents a hetcrocycle, imidazole, benzimidazole, isoxazole, tetrazole, oxadiazole, thiadazole, pyridine, quinazoline, quinoxaline, quinoline, thiophene; R1 represents COOR6, CONR6R7, CO—NH—CH(R6)—COOR7, CH2NR6R7, CH2OR6, (CH2)pR6, CH═CHR6; R2 represents in particular hydrogen, C1-C10 alkyl, a substituted or unsubstituted phenyl; R5 and R6 represents hydrogen, C1—C6 alkyl; R5 represents a substituted or unsubstituted phenyl or naphthyl; R6 and R7, identical or different, represent hydrogen, C1—C15 alkyl, a hetcrocycle. an aryl; n represents 0 to 10; p represents 1 to 6.

Potent and selective farnesyl transferase inhibitors

We recently described a novel series of CA1A2X peptidomimetics as farnesyl transferase inhibitors (FTIs). These compounds possess an N-(4-piperidinyl)benzamide scaffold mimicking A1A 2 residue. Extensive exploration of structure-activity relationships revealed that replacement of cysteine by substituted benzylimidazoles provided nanomolar FTIs with in vitro activities (18e, IC50 = 4.60 nM on isolated enzyme, EC50 = 20.0 nM for growth inhibition on a tumor cell line). The molecular docking of 18e and 19e in the active site of the enzyme provided details of key interactions with the protein and showed that the methionine or phenylalanine residue fits into the aryl binding site.

Parallel liquid synthesis of N,N′-disubstituted 3-amino azepin-2-ones as potent and specific farnesyl transferase inhibitors

A rapid structure-activity study was performed by parallel liquid synthesis on N,N′-disubstitution of 3-amino azepin-2-one to afford potent and specific farnesyl transferase inhibitors with low nM enzymatic and cellular activities. The activities of the selected compounds were validated in vivo, and compounds 41a and 44a presented significant antitumour activity.